Novo Nordisk, under new CEO Mike Doustdar, is changing its strategy to establish itself as a long-term leader in several obesity treatment segments rather than relying on a single flagship product.[1][2] The company is facing significant challenges in the American market, where rival company Eli Lilly has overtaken it in the position of leader.[1] As part of the restructuring, Novo Nordisk plans to cut about 9,000 jobs, representing about 11% of its global workforce.[5][6] The new CEO has instituted a global hiring freeze on new non-key employees and is emphasizing the need for greater financial discipline and efficiency.[1][4] The key ingredient semaglutide, which is part of the drugs Wegovy and Ozempic, generates approximately 60% of the company's future sales.[2] Novo Nordisk is pushing for a new $9 billion takeover bid for US biotech company Metsera.[2] While Eli Lilly builds on communication about maximum weight loss, Novo emphasizes a broader approach focused on treating obesity as a disease and related complications.[3]